Trained immunity: Consequences for the heterologous effects of BCG vaccination

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 109, Issue 1, 2014, Pages 29-35

  Kleinnijenhuis, Johanneke ^a   Van Crevel, Reinout ^a   Netea, Mihai G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BCG; Heterologous effects; Innate immunity; Trained immunity; Vaccine

Indexed keywords

BCG VACCINE; AUTACOID;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BCG VACCINATION; BLADDER CANCER; CD4+ T LYMPHOCYTE; CLINICAL PRACTICE; EPIGENETICS; HETEROLOGOUS IMMUNITY; HISTONE MODIFICATION; HODGKIN DISEASE; HUMAN; IMMUNITY; INFANT MORTALITY; INNATE IMMUNITY; INTRACELLULAR KILLING; LUNG CANCER; MACROPHAGE; MELANOMA; MONOCYTE; NATURAL KILLER CELL; NEWBORN SEPSIS; NONHUMAN; PROSTATE CANCER; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; TRAINED IMMUNITY; DRUG EFFECTS; EVIDENCE BASED MEDICINE; GENETIC EPIGENESIS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MANAGEMENT; MORTALITY; OBSERVATIONAL STUDY; T LYMPHOCYTE; TUBERCULOSIS;

ADAPTIVE IMMUNITY; BCG VACCINE; EPIGENESIS, GENETIC; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNITY, HETEROLOGOUS; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; INFLAMMATION MEDIATORS; OBSERVATIONAL STUDY AS TOPIC; POLICY MAKING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 84928890184     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/tru168     Document Type: Article

References (65)

1. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
2. Merrin C, Han T, Klein E et al. Immunotherapy of prostatic carcinoma with bacillus Calmette-Guerin. Cancer Chemother Rep 1975;59:157-63.
3. Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970;68:158-63.
4. McKneally MF, Maver C, Kausel HW. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet 1976;1:377-9.
5. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3.
6. Sokal JE, Aungst CW. Response to BCG vaccination and survival in advanced Hodgkin's disease. Cancer 1969;24:128-34.
7. El-Zein M, Parent ME, Benedetti A, Rousseau MC. Does BCG vaccination protect against the development of childhood asthma? A systematic review and meta-analysis of epidemiological studies. Int J Epidemiol 2010;39:469-86.
8. Faustman DL, Wang L, Okubo Y et al. Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One 2012;7:e41756.
9. Ristori G, Buzzi MG, Sabatini U et al. Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis. Neurology 1999;53:1588-9.
10. Sharquie KE, Al-Rawi JR, Al-Nuaimy AA, Radhy SH. Bacille Calmette-Guerin immunotherapy of viral warts. Saudi Med J 2008;29:589-93.
11. Bohle A, Buttner H, Jocham D. Primary treatment of condylomata acuminata with viable bacillus Calmette-Guerin. J Urol 2001;165:834-6.
12. Naeslund C. Experience wiht BCG vaccination in the province of Norrbotten (Sweden). Revue de la Tuberculose 1931;12:617-36.
13. Canadian Experience with BCG Vaccine. Can Med Assoc J 1936;35:196-7.
14. Levine MI, Sackett MF. Results of BCG immunization in New York City. Am Rev Tuberc 1946;53:517-32.
15. Aronson JD. Protective vaccination against tuberculosis, with special reference to BCG vaccine. Minn Med 1948;31:1336.
16. Ferguson RG, Simes AB. BCG vaccination of Indian infants in Saskatchewan. Tubercle 1949;30:5-11.
17. Mayr A. Taking advantage of the positive side-effects of smallpox vaccination. J Vet Med B Infect Dis Vet Public Health 2004;51:199-201.
18. Denny OE, Hopkins R. Specific leprous reactions and abnormal vaccinia induced in lepers by smallpox vaccination. Public Health Reports 1922;37:3141-9.
19. Schlavone GA. Smallpox vaccination in treatment of whooping cough. JAMA 1931;96:905.
20. Aaby P, Bukh J, Lisse IM, Smits AJ. Measles vaccination and reduction in child mortality: a community study from Guinea-Bissau. J Infect 1984;8:13-21.
21. Aaby P, Samb B, Simondon F et al. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ 1995;311:481-5.
22. Garly ML, Martins CL, Bale C et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine 2003;21:2782-90.
23. Aaby P, Gustafson P, Roth A et al. Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau. Vaccine 2006;24:5718-25.
24. Pfahlberg A, Kolmel KL, Grange JM et al. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J Invest Dermatol 2002;119:570-5.
25. Kolmel KF, Grange JM, Krone B et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 2005;41:118-25.
26. Aaby P, Jensen H, Samb B et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet 2003;361:2183-8.
27. Cooper WO, Boyce TG, Wright PF, Griffin MR. Do childhood vaccines have non-specific effects on mortality? Bull World Health Organ 2003;81:821-6.
28. Aaby P, Roth A, Ravn H et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011;204:245-52.
29. Martins CL, Benn CS, Andersen A et al. A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. J Infect Dis 2014;209:1731-8.
30. Steenhuis TJ, van Aalderen WM, Bloksma N et al. Bacille-Calmette-Guerin vaccination and the development of allergic disease in children: a randomized, prospective, single-blind study. Clin Exp Allergy 2008;38:79-85.
31. Lamm DL, Thor DE, Harris SC et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980;124:38-40.
32. Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Eng J Med 1991;325:1205-9.
33. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985-90.
34. Pearce L. Reciprocal effects of concomitant infections: III. The influence of vaccinia and of vaccinal immunity on the reaction to infection with experimental syphiilis (intracutaneous inoculation). J Exp Med 1928;48:363-77.
35. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002;2:417-26.
36. Virelizier JL, Allison AC, Schild GC. Antibody responses to antigenic determinants of influenza virus hemagglutinin. II. Original antigenic sin: a bone marrow-derived lymphocyte memory phenomenon modulated by thymus-derived lymphocytes. J Exp Med 1974;140:1571-8.
37. Mathurin KS, Martens GW, Kornfeld H, Welsh RM. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol 2009;83:3528-39.
38. Benn CS, Netea MG, Selin LK, Aaby P. A small jab - a big effect:nonspecific immunomodulation by vaccines. Trends Immunol 2013;34:431-9.
39. Sher NA, Chaparas SD, Greenberg LE, Bernard S. Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice. Infect Immun 1975;12:1325-50.
40. Tribouley J, Tribouley-Duret J, Appriou M. Effect of Bacillus Callmette Guerin (BCG) on the receptivity of nude mice to Schistosoma mansoni [in French]. C R Seances Soc Bio Fil 1978;172:902-4.
41. Kleinnijenhuis J, Quintin J, Preijers F et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012;109:17537-42.
42. Sakuma T, Suenaga T, Yoshida I, Azuma M. Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection. Infect Immun 1983;42:567-73.
43. Elberg SS, Schneider P, Fong J. Cross-immunity between Brucella melitensis and Mycobacterium tuberculosis; intracellular behavior of Brucella melitensis in monocytes from vaccinated animals. J Exp Med 1957;106:545-54.
44. Thanhauser A, Bohle A, Schneider B et al. The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 1995;40:103-8.
45. Howard JG, Biozzi G, Halpern BN et al. The effect of Mycobacterium tuberculosis (BCG) infection on the resistance of mice to bacterial endotoxin and Salmonella enteritidis infection. Br J Exp Pathol 1959;40:281-90.
46. Mackaness GB. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med 1969;129:973-92.
47. van 't Wout JW, Poell R, van Furth R. The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand J Immunol 1992;36:713-9.
48. Della Chiesa M, Marcenaro E, Sivori S et al. Human NK cell response to pathogens. Semin Immunol 2014;26:152-60.
49. Brandau S, Riemensberger J, JacobsenMet al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 2001;92:697-702.
50. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe 2011;9:355-61.
51. Price WC. Acquired immunity from plant virus diseases. Quart Rev Biol 1940;15:338-61.
52. Durrant WE, Dong X. Systemic acquired resistance. Ann Rev Phytopathol 2004;42:185-209.
53. Pham LN, Dionne MS, Shirasu-Hiza M, Schnieder DS. A specific primed immune response in Drosophila is dependent on phagocytes. PLoS Pathog 2007;3:e26.
54. Santos-Rosa H, Schneider R, Bannister AJ et al. Active genes are tri-methylated at K4 of histone H3. Nature 2002;419:407-11.
55. Slaughter A, Daniel X, Flors V et al. Descendants of primed Arabidopsis plants exhibit resistance to biotic stress. Plant Physiol 2012;158:835-43.
56. Kleinnijenhuis J, Quintin J, Preijers F et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun 2014;6:152-8.
57. Yanez A, Hassanzadeh-Kiabi N, Ng MYet al. Detection of a TLR2 agonist by hematopoietic stem and progenitor cells impacts the function of the macrophages they produce. Eur J Immunol 2013;43:2114-25.
58. Lara-Astiaso D, Weiner A, Lorenzo-Vivas E et al. Immunogenetics. Chromatin state dynamics during blood formation. Science 2014;345:943-9.
59. Wallgren A. B.C.G. vaccination; is it of any value in control of tuberculosis? Br Med J 1948;1:1126-9.
60. Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021-8.
61. Grode L, Ganoza CA, Brohm C et al. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013;31:1340-8.
62. Koike Y, Yoo YC, Mitobe M et al. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine. Vaccine 1998;16:1982-9.
63. Yoshikai Y, Ohga S, Takeda Y, Nomoto K. Effects of stimulated or immunologically activated macrophages on the induction of immune responses to Listeria monocytogenes. Immunobiology 1990;180:124-37.
64. Michel MY, Fathy FM, Hegazy EH et al. The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis. J Egypt Soc Parasitol 2006;36:159-76.
65. Alimohammadian MH, Khamesipour A, Darabi H et al. The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine 2002;21:174-80.